이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Devyser Diagnostics 대차 대조표 상태

재무 상태 기준 확인 5/6

Devyser Diagnostics 의 총 주주 지분은 SEK374.5M 이고 총 부채는 SEK500.0K, 이는 부채 대 자기자본 비율을 0.1% 로 가져옵니다. 총자산과 총부채는 각각 SEK496.6M 및 SEK122.1M 입니다.

주요 정보

0.1%

부채 비율

SEK 500.00k

부채

이자 보상 비율	n/a
현금	SEK 215.00m
주식	SEK 374.50m
총 부채	SEK 122.10m
총 자산	SEK 496.60m

최근 재무 상태 업데이트

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Recent updates

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Jun 14

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Mar 20

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Dec 09

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

Aug 30

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 14

재무 상태 분석

단기부채: DVYSR 의 단기 자산 ( SEK306.0M )이 단기 부채( SEK64.9M ).

장기 부채: DVYSR 의 단기 자산( SEK306.0M )이 장기 부채( SEK57.2M ).

부채 대 자본 내역 및 분석

부채 수준: DVYSR 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: DVYSR 의 부채 대 자기자본 비율은 지난 5년간 26.4% 에서 0.1% 로 감소했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: DVYSR 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: DVYSR 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Devyser Diagnostics 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Recent updates

Chief Executive Officer recently sold kr5.5m worth of stock

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Devyser Diagnostics AB (publ) Appoints Thomas Eklund as Member of the Board of Directors

Chief Executive Officer recently bought kr299k worth of stock

First quarter 2024 earnings released: kr0.75 loss per share (vs kr1.23 loss in 1Q 2023)

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software

Full year 2023 earnings: EPS misses analyst expectations

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Consensus estimates of losses per share improve by 66%

Devyser Diagnostics AB (publ) Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Insider selling

Devyser Diagnostics AB (Publ) Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024

Devyser Diagnostics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Chief Executive Officer recently bought kr1.5m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024

Consensus estimates of losses per share improve by 29%

Independent Director recently bought kr1.1m worth of stock

Consensus revenue estimates fall by 11%

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Devyser's Ngs Products for Monitoring of Kidney and Stem Cell Transplanted Patients Receive IVDR Approvals

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Devyser Announces its Deputy CEO and Founder Ulf Klangby Moves to Advisory Role

Chief Executive Officer recently bought kr105k worth of stock

Devyser Diagnostics AB Announces Approval of Devyser's RHD Product in Canada

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to kr1.89 loss

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 1,989%

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.55 loss per share (vs kr0.87 loss in 3Q 2021)

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Devyser Diagnostics AB (publ) Appoints John Murad as Vice President and General Manager in the US

Consensus EPS estimates fall by 66%

Second quarter 2022 earnings released: kr0.90 loss per share (vs kr0.94 loss in 2Q 2021)

Devyser Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Devyser Diagnostics AB (Publ) Appoints Camilla Wiberg as Chief HR Officer

Less than half of directors are independent

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Devyser Diagnostics AB (publ), Annual General Meeting, May 11, 2022

Less than half of directors are independent

Devyser Diagnostics AB (publ) Appoints Theis Kipling as Chief Commercial Officer

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ) to Report Q4, 2021 Results on Feb 24, 2022

Devyser Diagnostics AB (publ) (OM:DVYSR) agreed to acquire the remaining 70.1% stake in Smartseq S.R.L. from its three founders for €0.84 million.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기